Aadi Bioscience

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aadi Bioscience reports robust FYARRO sales and optimistic outlook for 2023

Aadi Bioscience showcased strong sales performance and financial stability in 2022.
The company's strengths lie in successful product launches, collaborations, and trial outcomes.
Challenges include managing expenses and meeting expectations for future data releases.
Excitement for 2023 signals potential growth opportunities and continued success.

Aadi Bioscience reports revenue growth and clinical progress in Q1

Aadi Bioscience demonstrated strong performance with revenue growth, progress in clinical trials, and a solid financial position.
The company's strengths lie in its product pipeline, clinical trial advancements, and financial stability, positioning it well for future growth.
While facing challenges in sales growth, trial timelines, and global expansion, Aadi Bioscience has opportunities to diversify its portfolio and explore new markets.

Aadi Bioscience reports robust Q2 earnings and expands pipeline offerings

Aadi Bioscience's Q2 performance reflects strong revenue growth, promising pipeline developments, and a solid financial position, positioning the company for future success.
While facing challenges in managing expenses and clinical trials, the company has opportunities to leverage its momentum, expand its market reach, and drive innovation.
Investors should take note of Aadi Bioscience's strategic advancements and financial stability, signaling potential for growth and value creation in the biopharmaceutical sector.

Aadi Bioscience reports solid Q3 results, advances cancer treatment innovations

Aadi Bioscience's Q3 performance reflects financial stability, increased expenses, and progress in advancing nab-Sirolimus for mutated cancers.
The company's strengths lie in new leadership, innovative treatment potential, and a tumor-agnostic trial approach, positioning it for future success.
Challenges include addressing analyst inquiries, meeting trial timeline goals, and managing financial resources effectively amidst growth and innovation.
Opportunities abound in potentially transforming cancer treatment, showcasing advancements, and expanding the pipeline with innovative approaches.

Aadi Bioscience reports robust sales growth and advances in cancer trials

Aadi Bioscience's strong financial performance in 2023, driven by robust FYARRO sales and a focus on operational efficiency, sets a solid foundation for future growth and innovation.
While challenges exist in managing R&D expenses and trial timelines, the company's strategic measures and positive outlook position them well to capitalize on opportunities in expanding their therapeutic reach.
With ongoing trials showing promising results and a proactive approach to presenting new data, Aadi Bioscience remains committed to advancing novel treatments and delivering value to patients and investors alike.

Aadi Bioscience reports steady Q1 sales and optimistic trial progress

Aadi Bioscience's Q1 performance reflects steady sales and strong cash position supporting future operations.
The company's focus on advancing clinical trials and strategic program alignment positions it for future growth.
Challenges in sales and collaboration changes present areas for ongoing monitoring and strategic adjustments.

Aadi Bioscience reports robust Q2 sales and advances in nab-Sirolimus trials

Aadi Bioscience's Q2 performance reflects steady growth in FYARRO sales and progress in nab-Sirolimus trials for various tumor types.
Despite challenges in meeting expectations and market dynamics, the company's strong financial position and confidence in its products are notable strengths.
With a cash runway into Q4 2025 and a promising pipeline, Aadi is poised for growth and success in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Aadi Bioscience, Inc. (AADI) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.66 per share a year ago.

Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates

Total 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients with appropriate follow-up in PRECISION 1 trial expected by end of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES , May 10, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced financial results for the first quarter of 2023 and provided an initial update on the tumor-agnostic PRECISION 1 trial, a registration-directed Phase 2 study of nab-sirolimus in patients with solid tumors with pathogenic inactivating alterations in TSC1 or TSC2 genes. "We are excited about the uptake of FYARRO and its continued sales growth after our first year on the market and believe we are operating from a position of strength with solid cash balances into 2025," said Scott Giacobello, Interim CEO and President and CFO of Aadi.

Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial

Company to Host Conference Call and Webcast on Wednesday, May 10, 2023 LOS ANGELES , May 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, May 10, 2023 at 8:30 am ET (5:30 am PT) to report first quarter 2023 financial results and provide an operational update. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at  aadibio.com.

Aadi Bioscience to Report First Quarter 2023 Results and Operational Update

LOS ANGELES , April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL.  The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial.

Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

LOS ANGELES , April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL.

Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting

LOS ANGELES , April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL.  The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I) " Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PM Session Title: Phase II and Phase III Clinical Trials in Progress  Presentation Number: CT057 Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors (KRASis) sotorasib and adagrasib in KRAS G12C NSCLC and bladder cancer xenografts" Date and Time: Tuesday, April 18, 2023, 1:30 - 5:00 PM Session Category: Clinical Research Excluding Trials Session Title: Poster Combination Therapies for Cancer Presentation Number: 5484 Title: " Biomarker analysis from AMPECT correlating response to nab-sirolimus with TSC1 and TSC2 inactivating alterations " Date and Time: Wednesday, April 19, 2023, 9:00 AM - 12:30 PM Session Category: Clinical Research Excluding Trials Session Title: Late-Breaking Research: Clinical Research 3 Presentation Number: LB288 Full session and meeting details are available through the AACR Annual Meeting planner: AACR Annual Meeting 2023 | Meetings | AACR.

Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q4 2022 Earnings Conference Call March 28, 2023 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations and Corporate Communications Neil Desai - Founder and Executive Chairman Scott Giacobello - Interim Chief Executive Officer, President, and Chief Financial Officer Loretta Itri - Chief Medical Officer Conference Call Participants Roger Song - Jefferies LLC Ahu Demir - Ladenburg Thalmann & Company Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience Fourth Quarter 2022 Earnings Call.

Aadi Bioscience, Inc. (AADI) Q4 2022 Earnings Call Transcript

Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of 20% and 14.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Tops Revenue Estimates

Total revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES , March 28, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the fourth quarter and full-year 2022. "2022 was a year marked by successive milestones with the launch of FYARRO, the start of the PRECISION 1 trial, strengthening our balance sheet with a $72.5 million financing, taking our cash runway into 2025, and collaborating on a new combination of nab-sirolimus with Mirati's adagrasib," said Scott Giacobello, CFO and interim President and CEO of Aadi Bioscience.

Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update

LOS ANGELES , March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors.

Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors

LOS ANGELES , March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL. "We are pleased to present additional data with nab-sirolimus from our AMPECT trial and highlight our PRECISION 1 trial at SGO 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said Loretta Itri, MD.

Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer

Company to Host Conference Call and Webcast on March 28, 2023 LOS ANGELES , March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Tuesday, March 28, 2023 at 8:30 am EDT (5:30 am PDT) to report fourth quarter and full-year 2022 financial results and provide recent corporate updates. Conference Call Information  Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com.

Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update

AADI is a commercial stage company with a potential label expansion ahead. It is adequately funded, run by expert management, and has a major catalyst next year.

Aadi Bioscience: Commercial Stage With Large Market In Label Expansion

LOS ANGELES , March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company. Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities.

Aadi Bioscience Announces Leadership Transition

LOS ANGELES , Feb. 22, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, announced today participation at the 43rd Annual Healthcare Conference being held March 6-8, 2023, in Boston, MA. Brendan Delaney, Aadi Bioscience CEO, will join in a panel discussion entitled, "Tumor Agnostic Development," on Wednesday, March 8, 2023 at 9:10 AM ET.

Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference

Aadi Bioscience, Inc. (AADI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aadi Bioscience, Inc. (AADI) Upgraded to Buy: What Does It Mean for the Stock?

Trial-in-progress poster showcases clinical trial design for PRECISION 1 and two additional posters demonstrate favorable durability of response and long-term safety of nab-sirolimus in the completed AMPECT study LOS ANGELES , Nov. 17, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented three posters on completed and ongoing clinical trials for nab-sirolimus at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place November 16-19, 2022 in Vancouver, Canada. nab-sirolimus (FYARRO®) is a novel mTOR inhibitor that leverages albumin-bound nanoparticle technology and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

Aadi Bioscience, Inc. (NASDAQ:AADI ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Marcy Graham - Senior Vice President of Investor Relations & Corporate Communications Neil Desai - President & Chief Executive Officer Brendan Delaney - Chief Operating Officer Loretta Itri - Chief Medical Officer Scott Giacobello - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Boris Peaker - Cowen Joseph Catanzaro - Piper Sandler Operator Good day and thank you for standing by. Welcome to the Aadi Bioscience, Inc. Third Quarter Earnings Conference Call.

Aadi Bioscience, Inc. (AADI) Q3 2022 Earnings Call Transcript

Completed $72.5 million PIPE financing extending cash runway into 2025 PRECISION 1 trial on-track with preliminary data expected in the first half of 2023 24% revenue growth of FYARRO® (nab-sirolimus) over the second quarter 2022 Appointment of Neil Desai to Executive Chairman and transition of Brendan Delaney to CEO effective January 1, 2023 Conference call to be held today at 8:30 am ET LOS ANGELES , Nov. 9, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the third quarter of 2022. "The last several months have been transformational for Aadi, most recently having strengthened our balance sheet with a $72.5 million PIPE financing.

Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update

LOS ANGELES , Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023.  "I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021.

Aadi Bioscience Announces Planned Leadership Transition

LOS ANGELES , Nov. 3, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences during November: H.C. Wainwright 3rd Annual Precision Oncology Virtual Conference, November 14, 2022 Neil Desai, Ph.D.

Aadi Bioscience to Present at Upcoming Investor Conferences

Company to Host Conference Call and Webcast on November 9 LOS ANGELES , Nov. 2, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Wednesday, November 9, 2022 at 8:30 am ET (5:30 am PT) to report third quarter 2022 financial results and provide recent corporate updates. Conference Call Information   Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at  aadibio.com.

Aadi Bioscience to Report Third Quarter 2022 Results and Corporate Update

Nab-sirolimus added to KRAS inhibitor treatment demonstrated significantly greater antitumor activity and tumor regressions compared to the KRAS inhibitors alone The KRAS inhibitor combinations with nab-sirolimus were significantly more active than the corresponding everolimus combinations LOS ANGELES , Oct. 27, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today presented preclinical combination data of KRAS inhibitors and nab-sirolimus at the 34th EORTC-NCI-AACR Symposium. Nab-sirolimus is a novel albumin-bound nanoparticle form of the mTOR inhibitor sirolimus and is approved for the treatment of locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium

Mirati Therapeutics

SAN DIEGO and LOS ANGELES , Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors. The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C - mutant solid tumors.

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation

LOS ANGELES , Sept. 22, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of its common stock ("Common Stock") at a price of $12.50 per share, reflecting the closing price on September 21, 2022 on NASDAQ, and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 2,426,493 shares of Common Stock at a purchase price of $12.4999 per pre-funded warrant share, through a private investment in public equity ("PIPE") financing.

News for Aadi Bioscience Stock (AADI)